Entrada Therapeutics, Inc. Common Stock (TRDA) Stock Price

TRDAStock

$7.62+19.38%52W

Market Cap$296.70M

P/E7.40x

PEG Ratio—

Div yield—

Beta-0.27

TRDA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-44.85%

Price vs S&P 500 (4W)22.68%

VGM Score39.62

P/E Ratio (Annual)7.40x

Book Value / Share (Quarterly)$5.99

P/TBV (Annual)1.80x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-3.45

Price vs S&P 500 (YTD)-40.66%

Net Profit Margin (TTM)-3537.73%

EPS (TTM)$-3.97

10-Day Avg Trading Volume0.21M

EPS Excl Extra (TTM)$-3.97

EPS (Annual)$-3.47

ROI (Annual)-46.96%

Cash / Share (Quarterly)$5.73

Revenue Growth QoQ (YoY)-53.95%

P/E Normalized (Annual)7.40x

ROA (Last FY)-38.09%

Revenue Growth TTM (YoY)-94.10%

EBITD / Share (TTM)$-4.13

ROE (5Y Avg)-19.21%

Operating Margin (TTM)-3767.07%

Cash Flow / Share (Annual)$-3.38

P/B Ratio1.24x

P/B Ratio (Quarterly)1.22x

Net Income / Employee (Annual)$-945,700

EV / Revenue (TTM)40.72x

Net Interest Coverage (TTM)-1704.33x

ROA (TTM)-46.54%

EV / EBITDA (TTM)26.79x

EPS Incl Extra (Annual)$-3.47

Current Ratio (Annual)12.53x

Quick Ratio (Quarterly)10.47x

3-Month Avg Trading Volume0.41M

52-Week Price Return19.38%

Revenue / Employee (TTM)$30,800

Tangible BV / Share (Quarterly)$7.40

P/S Ratio (Annual)11.41x

Asset Turnover (Annual)0.07x

52-Week High$16.45

EPS Excl Extra (Annual)$-3.47

CapEx CAGR (5Y)-14.88%

26-Week Price Return-33.61%

Quick Ratio (Annual)12.17x

13-Week Price Return16.16%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)10.89x

Enterprise Value$190.80M

Asset Turnover (TTM)0.01x

Revenue / Employee (Annual)$167,200

Pretax Margin (Annual)-561.84%

Cash / Share (Annual)$7.72

3-Month Return Std Dev66.21%

Net Income / Employee (TTM)$-1,090,600

ROE (Last FY)-46.96%

EPS Basic Excl Extra (Annual)$-3.47

P/FCF (TTM)3.45x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-3.97

ROI (TTM)-57.61%

P/S Ratio (TTM)61.90x

Revenue / Share (Annual)$0.61

Tangible BV / Share (Annual)$6.77

Price vs S&P 500 (52W)1.07%

Year-to-Date Return-28.70%

5-Day Price Return0.83%

EPS Normalized (Annual)$-3.47

ROA (5Y Avg)-16.26%

Net Profit Margin (Annual)-565.48%

Month-to-Date Return7.95%

Cash Flow / Share (TTM)$-0.58

EBITD / Share (Annual)$-3.72

Operating Margin (Annual)-621.13%

ROI (5Y Avg)-19.21%

EPS Basic Excl Extra (TTM)$-3.97

P/TBV (Quarterly)1.55x

P/B Ratio (Annual)1.28x

Pretax Margin (TTM)-3520.25%

Book Value / Share (Annual)$8.00

Price vs S&P 500 (13W)13.37%

Beta-0.27x

P/FCF (Annual)2.16x

Revenue / Share (TTM)$0.11

ROE (TTM)-57.61%

52-Week Low$5.02

vGradeC

gGradeF

mGradeB

vgmGradeD

TRDA Earnings Surprise History

Q2 25-1.04est. -0.86

Q3 25-1.06est. -0.96

Q4 25-0.94est. -1.16

Q1 26-0.95est. -1.02

Q2 26-1.01est. -1.04

TRDA Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.29

4.21

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
TRDAEntrada Therapeutics, Inc. Common Stock	C	F	B	$7.62
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Entrada Therapeutics, Inc. Common Stock

Entrada Therapeutics is a clinical-stage biopharmaceutical company developing medicines to treat neuromuscular and ocular diseases using its proprietary Endosomal Escape Vehicle (EEV) platform, which enables efficient delivery of therapeutic molecules into cells. The company's pipeline focuses on oligonucleotide therapies for Duchenne muscular dystrophy through multiple exon-skipping approaches, and includes a partnered program for myotonic dystrophy type 1. By targeting previously inaccessible intracellular sites, Entrada aims to improve therapeutic efficacy for serious genetic diseases.